Skip to main content

Kennedy Giulia C's Form 4/A amendment

Amended

Veracyte, Inc. (VCYT) · filed Mar 9, 2022

Accession no.
0001384101-22-000054
Filed
Mar 9, 2022
Trade date
Mar 3-4, 2022
Filing delay
6 days
Rule 10b5-1 plan
Not on the form (before 2023)
Original filed
Mar 7, 2022

This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $578.5K. It was filed 6 days after the trade.

This amendment replaces 0001384101-22-000046 (filed Mar 7, 2022).

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Kennedy Giulia CCIK 0001769333Officer (Chief Scientific & Med Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 3, 2022Common StockAGrant or awardAcquired+42,412$0.00$079,987Direct
Mar 4, 2022Common StockMOption exerciseAcquired+4,407$5.98+$26,353.8684,394Direct
Mar 4, 2022Common StockSSaleDisposed−17,089$24.91F3−$425,686.9967,305Direct
Mar 4, 2022Common StockSSaleDisposed−5,844$25.70F4−$150,190.861,461Direct
Mar 4, 2022Common StockSSaleDisposed−100$26.49−$2,64961,361Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 3, 2022Common StockAGrant or awardAcquired+77,287$0.00$077,287Direct
Mar 4, 2022Common StockMOption exerciseDisposed−4,407$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Restricted stock units awarded on March 3, 2022 vest 25% on March 2, 2023 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date.

F2

The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021.

F3

Represents weighted average sales price. Sale prices for the transactions range from $24.40 to $25.40. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

Referenced by the price of 1 transaction in Table I.

F4

Represents weighted average sales price. Sale prices for the transactions range from $25.41 to $26.26. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

Referenced by the price of 1 transaction in Table I.

F5

The option becomes exercisable as to 25% of the shares on March 3, 2023, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.

F6

The option is fully vested.

Remarks

This amendment to Form 4 filed on March 7, 2022 is filed to correct the amount of securities sold on March 4, 2022 and the sale price applicable thereto as reflected in Column 4 of Table 1.

Read the full filing on SEC EDGAR (opens in a new tab)